RxDoctor Payments DataLook up a doctor →

Vincent Sollecito, DPM

Foot & Ankle Surgery · Saint Louis, MONPI 1649236357

Payments from drug & device makers

$221,047in general payments, 2019–2025

Across 488 payments — averaging $452.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Convatec Inc.$154K
  • Smith+Nephew$52K
  • Triad Life Sciences Inc.$11K
  • Elite Orthopedics, LLC$1K
  • Stryker$846
  • Organogenesis Inc.$588
  • plus $2K from 23 others

What the payments were for

  • Consulting fees$133,20660%
  • Speaking & faculty fees$38,41417%
  • Travel & lodging$35,01916%
  • Food & beverage$13,2076%
  • Education$1,2001%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$221,047 in reported general payments places this provider in the 95th percentile of 163 foot & ankle surgery providers in Missouri.

See all foot & ankle surgery providers in Missouri

Medicare billing

Part B allowed, 2024
$190,442
Medicare patients
373
Services billed
1,856

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.17$8,843
Pentoxifylline14$946
Gabapentin33$427
Mupirocin59$421
Doxycycline Hyclate41$401
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen45$296
Triamcinolone Acetonide26$180
Ammonium Lactate15$177
Ciprofloxacin Hcl18$163
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$106
Meloxicam22$36

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$51,853$8,84317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 163 foot & ankle surgery providers in Missouri.

Other foot & ankle surgery in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →